^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Immune Checkpoint Inhibitor Predictive Response Signature

    Company:
    Genecentric
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    GeneCentric has developed an Immune Checkpoint Inhibitor Predictive Response Signature (ICI-PRS) with genes associated with improved survival in ICI-treated patients, but not in standard-of-care treated patients. This predictive multi-feature signature is comprised of immune and tumor biology that can complement TMB and is vastly superior to current PD-L1 biomarker tests.
    Cancer:
    Solid Tumor
    Gene:
    PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)
    Method:
    RNA-based molecular screening test